Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hemp Naturals, Inc. (HPMM)
Sunny Isles Beach, FL, US
Hemp Naturals, Inc. operates as a burgeoning enterprise, focusing on the research, development, acquisition, and sale of products derived from industrial hemp. Its current offerings include rolling papers, which are distributed across 25 retail locations such as gas stations, convenience stores, tobacco shops, and liquor stores. The company plans to expand its product line to encompass a wider array of consumer goods utilizing industrial hemp and/or the non-psychoactive components of the cannabis plant. This future range is expected to feature items like nutritional hemp health supplements, hemp-based food products (including shakes), beauty supplies, and apparel crafted from hemp. Established in 2015, Hemp Naturals, Inc. maintains its headquarters in Sunny Isles Beach, Florida.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +1,900.00% | -80.00% | -80.00% | +1,900.00% | -80.00% | -80.00% | -80.00% | -99.51% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-142.9% Q1'22: +99.9% (vs Q1'21)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-107,280.1%
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-107,276.9%
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-837.6% Q1'22: -4.6% (vs Q1'21)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+236.9% Q1'22: +75.5% (vs Q1'21)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× Q1'22: -0.54× (vs Q1'21)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Levi Jacobson | Chief Executive Officer, President, Chief Financial Officer, Chief Operating Officer, Chief Accounting Officer & Director | 65.5K | male |
| Maryna Bleier | Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HPMM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
